The first is tissue-type plasminogen activator (Tpa) which is involved in plasminogen conversion into plasmin (a main enzyme responsible for clot breakdown) that is currently used in medical applications, and which was the only previously approved pharmacological treatment for restoring blood flow after a stroke occurred50. This evidence concerns the gene PLAT and Stroke.